Explosion at Chinese pharmaceutical plant leaves 10 dead

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Mputsylo)
(Image: Getty/Mputsylo)

Related tags China Qilu Tianhe Huishi Pharmaceuticals Gsk

Dozens hurt and 10 people dead after an accident during renovation work in Shandong province, China.

The company involved, Qilu Tianhe Huishi Pharmaceuticals, had ordered maintenance work to be carried out on underground piping, which subsequently caused an explosion, according to local media reports​.

It was reported that welding of the piping caused a heat-transferring substance to ignite, causing an explosion and resulted in 10 workers dying of smoke inhalation, with a further 12 suffering minor injuries.

The local city government of Jinan are investigating the causes of the accident.

Qilu Tianhe specialises in the production of generic drugs and active pharmaceutical ingredients, with the company noting on its website that all of its products have passed the Chinese GMP standard.

The company involved did not respond to a request for comment.

In 2015​, a GlaxoSmithKline owned facility suffered an explosion in Tianjin, China. The situation led to the facility’s good manufacturing practice (GMP) certification being revoked by the UK’s regulatory body.

More recently, there was a national outcry after vaccines that were administered to children across the country were found to be improperly manufactured or substandard. The case led to a number of officials being dismissed​.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more